Financial Analysis: Corbus Pharmaceuticals (NASDAQ:CRBP) vs. VYNE Therapeutics (NASDAQ:VYNE)

Corbus Pharmaceuticals (NASDAQ:CRBP) and VYNE Therapeutics (NASDAQ:VYNE) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, valuation, dividends, analyst recommendations, earnings and institutional ownership.

Profitability

This table compares Corbus Pharmaceuticals and VYNE Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Corbus Pharmaceuticals	N/A	-70.89%	-61.78%
VYNE Therapeutics	-4,726.21%	-70.42%	-63.46%

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Corbus Pharmaceuticals and VYNE Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corbus Pharmaceuticals	2	0	9	1	2.75
VYNE Therapeutics	1	3	0	0	1.75

Corbus Pharmaceuticals presently has a consensus price target of $40.67, suggesting a potential upside of 363.17%. Given Corbus Pharmaceuticals’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Corbus Pharmaceuticals is more favorable than VYNE Therapeutics.

Risk and Volatility

Corbus Pharmaceuticals has a beta of 2.57, meaning that its stock price is 157% more volatile than the S&P 500. Comparatively, VYNE Therapeutics has a beta of 2, meaning that its stock price is 100% more volatile than the S&P 500.

Institutional & Insider Ownership

64.6% of Corbus Pharmaceuticals shares are held by institutional investors. Comparatively, 83.8% of VYNE Therapeutics shares are held by institutional investors. 3.5% of Corbus Pharmaceuticals shares are held by company insiders. Comparatively, 3.0% of VYNE Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Corbus Pharmaceuticals and VYNE Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corbus Pharmaceuticals	N/A	N/A	-$78.54 million	($5.82)	-1.51
VYNE Therapeutics	$570,000.00	37.80	-$26.48 million	($0.38)	-1.70

VYNE Therapeutics has higher revenue and earnings than Corbus Pharmaceuticals. VYNE Therapeutics is trading at a lower price-to-earnings ratio than Corbus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Corbus Pharmaceuticals beats VYNE Therapeutics on 9 of the 14 factors compared between the two stocks.

About Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

About VYNE Therapeutics

VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.